ImmunoGen, Inc. Announces Webcast of Presentation at the Lazard Capital Markets Third Annual Life Sciences Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 21, 2006--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the Lazard Capital Markets Third Annual Life Sciences Conference will be webcast live. The 25-minute presentation is scheduled to begin at 11:30 a.m. EST on November 28, 2006, and will be given at the New York Palace Hotel in New York City. The presentation will provide an update on ImmunoGen.
The webcast can be accessed through the "Investor Relations" section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the same location until December 5, 2006.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Five anticancer compounds are in clinical testing through ImmunoGen and the Company's collaborators - huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Amgen (formerly Abgenix), Biogen Idec, Biotest AG, Boehringer Ingelheim, Centocor (Johnson & Johnson), Genentech, Millennium Pharmaceuticals, Inc., and sanofi-aventis have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with sanofi-aventis.
CONTACT: Investors:
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations and Corporate
Communications
info@immunogen.com
SOURCE: ImmunoGen, Inc.
